Retigabine dihydrochloride

Research use only, not for human use.

Retigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current.

Retigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current. The effect of retigabine was associated with a slowing of M-like tail current deactivation in these cells. Retigabine (0.1 to 10 microM) induced a potassium current and hyperpolarized CHO cells expressing KCNQ2/Q3 cells but not in wild-type cells. Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM). The mechanism by which retigabine enhanced KCNQ2/Q3 currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine). Retigabine shifted the voltage dependence of channel activation with an EC(50) value of 1.6 +/- 0.3 microM (slope factor was 1.2 +/- 0.1, n = 4 to 5 cells per concentration). Retigabine (0.1 to 10 microM) also slowed the rate of channel deactivation, predominantly by increasing the contribution of a slowly deactivating tail current component.

——

——

Ezogabine,D-23129

Cell Cycle/DNA Damage

Potassium Channel

KCNQ3/5|KCNQ2/Q3|KCQN4

——

——

150812-13-8

376.25

C16H20Cl2FN3O2

>98% (HPLC)

——

Cl.Cl.CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N

——

(-20℃)

With Ice Pack

≥ 2 years